Mode
Text Size
Log in / Sign up

Self-weaning shows no significant difference from dose-adjusted weaning in caffeine duration for apnea of prematurityCaffeine weaning methods show no difference for preterm infants

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that self-weaning and dose-adjusted weaning show no significant difference in caffeine duration for apnea of prematurity.

This prospective cohort study evaluated 204 preterm infants discharged home on caffeine for apnea of prematurity. The study compared self-weaning, where the absolute dose remained fixed as weight increased, to dose-adjusted weaning, where the dose was recalculated based on current weight at each visit.

Primary outcomes included the proportion of infants continuing caffeine beyond 36 weeks postmenstrual age (PMA) and caregiver-reported apnea after discontinuation. The self-weaning group had 68/94 (72.3%) continuing caffeine beyond 36 weeks PMA, while the dose-adjusted group had 84/110 (76.4%). The adjusted OR was 0.82 (95% CI 0.43 to 1.57), which was not significant. Time to discontinuation showed an adjusted HR of 1.21 (95% CI 0.91 to 1.60), also not significant.

Secondary outcomes included apnea-related readmission on caffeine, which occurred in 1/94 (1.1%) of the self-weaning group and 2/110 (1.8%) of the dose-adjusted group. No apnea was reported by caregivers in either group following discontinuation.

Limitations include the study design not being a randomized trial and a lack of objective home monitoring. Because the results show no significant difference in weaning outcomes, self-weaning may be a practical alternative to dose-adjusted weaning, though evidence certainty is low.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in management strategies for apnea of prematurity. While previous coverage noted that multimodal lung-protective strategies reduce BPD risk in preterm infants, this study specifically addresses the weaning protocols for caffeine therapy in those same infants. The results suggest that self-weaning is comparable to dose-adjusted weaning regarding duration of treatment and safety.

When babies are born too early, they often struggle to breathe on their own. Doctors use caffeine to help them stay awake and breathe steadily. However, deciding when and how to stop that caffeine is a careful process. This study looked at two ways to do it: a simple method where the dose stays the same as the baby grows, and a complex method where the dose is recalculated based on the baby's weight at every visit.

Researchers followed 204 preterm infants in Pakistan to see which method worked better. They looked at how long babies stayed on caffeine and if they had breathing issues after stopping. The results showed no significant difference between the two methods. In both groups, the number of babies still needing caffeine at 36 weeks was similar, and neither group reported breathing problems after the caffeine was stopped.

While the results are promising for simplifying care, the study has some limits. It was not a randomized trial, and researchers could not monitor the babies at home. Because of these factors, the evidence is currently considered low certainty, but it suggests that simpler weaning plans might be a practical option for doctors.

What this means for you:
Simpler caffeine weaning methods for preterm infants showed no significant difference compared to complex dose adjustments.

Common questions

Is the simpler weaning method safe for babies?

The study found no significant difference in safety or outcomes between the two methods. In both the self-weaning and dose-adjusted groups, no cases of apnea (breathing pauses) were reported by caregivers after the caffeine was stopped. However, because this was not a randomized trial, you should talk to a doctor about the best plan for a specific infant.

How many babies were in the study?

The study included a total of 204 preterm infants who were discharged home while still receiving caffeine for apnea of prematurity. The group using the simpler self-weaning method had 94 infants, while the group using the dose-adjusted method had 110 infants.

What is the difference between self-weaning and dose-adjusted weaning?

Self-weaning means the caffeine dose stays fixed while the baby's weight increases. Dose-adjusted weaning means the dose is recalculated based on the baby's current weight at every visit. The study found that both methods resulted in similar rates of babies needing caffeine beyond 36 weeks.

Study Details

Study typeRct
EvidenceLevel 2
PublishedSep 2026
View Original Abstract ↓
Objective: To compare self-weaning and dose-adjusted caffeine regimens in preterm infants discharged home on caffeine for apnea of prematurity (AOP). Design: A prospective cohort study. Setting: Tertiary neonatal unit and outpatient clinics, Karachi, Pakistan, April 2023 to July 2025. Patients: 204 preterm infants (<37 weeks' gestation) discharged home on caffeine for AOP; 94 self-weaning, 110 dose adjusted. Interventions: Self-weaning (absolute dose fixed, so mg/kg/day exposure declined with weight gain) versus dose-adjusted weaning (dose recalculated to current weight at each visit). Both were followed to 36 weeks postmenstrual age (PMA). Main outcome measures: Proportion continuing caffeine beyond 36 weeks PMA and caregiver-reported apnea after discontinuation. Results: Caffeine was continued beyond 36 weeks PMA in 68/94 self-weaning infants (72.3%) and 84/110 dose-adjusted infants (76.4%). No apnea was reported after discontinuation in either group, and all 204 infants survived to 36 weeks PMA. Apnea-related readmission on caffeine occurred in 1/94 (1.1%) versus 2/110 (1.8%). Weight at discontinuation was lower with self-weaning (1917 vs 2157g); the dose-adjusted group was more premature (mean 30.0 vs 30.7 weeks). After adjustment for gestational age and birth weight, regimen was not associated with continuation beyond 36 weeks (adjusted OR 0.82, 95% CI 0.43 to 1.57) or time to discontinuation (adjusted HR 1.21, 95% CI 0.91 to 1.60). Conclusions: Within a structured outpatient follow-up program, no post-discontinuation apnea was reported with either regimen,and apnea-related readmissions were infrequent. Self-weaning avoids repeated dose recalculation. A multicenter randomized trial with objective home monitoring is needed to determine the optimal timing of discontinuation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.